Homes
Public Notices
News
Local news
Editor’s Pick
Pittsburgh
Local Government
Roads, Travel and Traffic
20 Years of Gas Drilling
Regional
U.S. and World
Business
Sports
HS Sports
College Sports
Penguins
Pirates
Steelers
Athlete of the Week
Wild Things
Pony Baseball
Outdoors
Columns
Opinion
Columns
Editorials
Letters to the Editor
Op Eds
Living
Neighbors
School News
Entertainment
Home and Garden
Food
Police Beat
Obituaries
Classifieds
Legal Notices
Sponsored Content
e-Edition
close
Washington County
Greene County
Mon Valley
News
Local news
Police Beat
Pittsburgh
Local Government
Roads, Travel and Traffic
Helping The Helpers
20 Years of Gas Drilling
Regional
U.S. and World
Business News
Sports
High School Sports
College Sports
Penguins
Pirates
Steelers
Wild Things
Pro Sports
Outdoors
Sports Column
Obituaries
Opinion
Columns
Editorials
Letters to the Editor
Op-Ed
Living
Neighbors
Health and Wellness
Entertainment
Home and Garden
Classifieds
Contact Us
Advertise With Us
Customer Service
Contact Information
Submission Forms
Statement of Values
Misc
Special Sections
Events
Sponsored Content
Newsletter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
REGENXBIO Inc. - Common Stock
(NQ:
RGNX
)
11.16
-0.44 (-3.79%)
Streaming Delayed Price
Updated: 4:00 PM EST, Jan 30, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
1,010,011
Open
11.23
Bid (Size)
11.15 (100)
Ask (Size)
11.50 (100)
Prev. Close
11.60
Today's Range
10.97 - 11.56
52wk Range
5.035 - 16.19
Shares Outstanding
43,466,186
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Kaplan Fox Alerts Investors of REGENXBIO Inc. (RGNX) to an Investigation of Possible Securities Law Violations
January 28, 2026
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.
Via
NewMediaWire
Kaplan Fox Alerts Investors of REGENXBIO Inc. (RGNX) to an Investigation of Possible Securities Law Violations
January 28, 2026
Via
TheNewswire.com
Performance
YTD
-17.8%
-17.8%
1 Month
-17.8%
-17.8%
3 Month
-6.9%
-6.9%
6 Month
+34.0%
+34.0%
1 Year
+42.7%
+42.7%
More News
Read More
RGNX Shares Pare Losses As Wall Street Dismisses Gene Therapy Clinical Hold Spurred Selloff As An Overreaction
↗
January 28, 2026
Via
Stocktwits
Gapping stocks in Wednesday's session
↗
January 28, 2026
Via
Chartmill
RGNX Stock Is Falling Today — What Is The FDA Update On REGENXBIO's Gene Therapy?
↗
January 28, 2026
Via
Stocktwits
Earnings Scheduled For November 6, 2025
↗
November 06, 2025
Via
Benzinga
Analyst Expectations For Regenxbio's Future
↗
August 19, 2025
Via
Benzinga
Earnings Scheduled For August 7, 2025
↗
August 07, 2025
Via
Benzinga
Top movers in Wednesday's pre-market session
↗
January 28, 2026
Via
Chartmill
My Top 4 Stocks to Buy in Early 2026
↗
January 22, 2026
Via
The Motley Fool
Topics
Artificial Intelligence
Economy
Capricor Therapeutics (NASDAQ: CAPR) Soars 535% to Eight-Year High on Landmark Duchenne Muscular Dystrophy Treatment Results
December 03, 2025
Via
MarketMinute
REGENXBIO (RGNX) Q3 2025 Earnings Call Transcript
↗
November 27, 2025
Via
The Motley Fool
Topics
Earnings
REGENXBIO INC (NASDAQ:RGNX) Tops Q3 2025 Estimates, Shares Rise on Strong Results and Pipeline Progress
↗
November 06, 2025
Via
Chartmill
The Analyst Verdict: Regenxbio In The Eyes Of 7 Experts
↗
October 07, 2025
Via
Benzinga
7 Analysts Assess Regenxbio: What You Need To Know
↗
October 07, 2025
Via
Benzinga
A Glimpse Into The Expert Outlook On Regenxbio Through 6 Analysts
↗
September 08, 2025
Via
Benzinga
Regenxbio Unveils 12-Month Data For Gene Therapy Soon After FDA Delays Review Date
↗
September 05, 2025
Via
Benzinga
Navigating the Currents: Top Sectors Primed for Growth in Q3 2025
August 27, 2025
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Retirement
FDA Extends Decision Date On Regenxbio's Gene Therapy Into Next Year
↗
August 19, 2025
Via
Benzinga
REGENXBIO INC (NASDAQ:RGNX) Reports Q2 2025 Earnings Miss, Stock Slides Amid Revenue and EPS Shortfalls
↗
August 07, 2025
Via
Chartmill
Topics
Earnings
A Glimpse Into The Expert Outlook On Regenxbio Through 8 Analysts
↗
June 09, 2025
Via
Benzinga
Crude Oil Moves Higher; Ciena Posts Downbeat Earnings
↗
June 05, 2025
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
↗
June 05, 2025
Via
Benzinga
Early Wins: RegenXBio's Gene Therapy Helps Duchenne Patients Walk Stronger, Longer
↗
June 05, 2025
Via
Benzinga
Dow Dips Over 100 Points; US Jobless Claims Increase
↗
June 05, 2025
Via
Benzinga
Topics
Stocks
Frequently Asked Questions
Is REGENXBIO Inc. - Common Stock publicly traded?
Yes, REGENXBIO Inc. - Common Stock is publicly traded.
What exchange does REGENXBIO Inc. - Common Stock trade on?
REGENXBIO Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for REGENXBIO Inc. - Common Stock?
The ticker symbol for REGENXBIO Inc. - Common Stock is RGNX on the Nasdaq Stock Market
What is the current price of REGENXBIO Inc. - Common Stock?
The current price of REGENXBIO Inc. - Common Stock is 11.16
When was REGENXBIO Inc. - Common Stock last traded?
The last trade of REGENXBIO Inc. - Common Stock was at 01/30/26 04:00 PM ET
What is the market capitalization of REGENXBIO Inc. - Common Stock?
The market capitalization of REGENXBIO Inc. - Common Stock is 485.08M
How many shares of REGENXBIO Inc. - Common Stock are outstanding?
REGENXBIO Inc. - Common Stock has 485M shares outstanding.
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
Starting at $3.75
/
week.
Subscribe Today